A Study of RC18 Administered Subcutaneously to Subjects With IgA(Immunoglobulin A) Nephropathy
Primary Purpose
IgA Nephropathy
Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
RC18 160mg
RC18 240mg
placebo
Sponsored by
About this trial
This is an interventional treatment trial for IgA Nephropathy
Eligibility Criteria
Inclusion Criteria:
- Signing the informed consent;
- Biopsy confirmed diagnosis of IgA nephropathy;
- Male or female, between 18 and 70 years age;
- Before randomization, 24-hour urine protein excretion of ≥1g/24h in every screening visit;
- Estimated glomerular filtration rate (eGFR) (CKD-EPI formula) of >45 ml/min per 1.73m2;
- Have received the ACEI(Angiotension converting enzyme inhibitors)/ARB(Angiotensin receptor blocker) standard treatment for 24 weeks prior to randomization, and have stabled the dosage (within the maximum tolerated dosage) for 4 weeks prior to randomization.
Exclusion Criteria:
Significant abnormalities in clinical laboratory values (including, but not limited to, the following indicators):
Items Abnormal value WBC(white blood cell count) <3*10^9/L PMN(Neutrophil count) <1.5*10^9/L HGB(hemoglobin) <85g/L PLT(blood platelet count) <80*10^9/L TBil(total bilirubin) >1.5*ULN ALT(Alanine aminotransferase) >3*ULN AST( Aspartate transaminase) >3*ULN ALP(alkaline phosphatase) >2*ULN CK(creatine kinase) >5*ULN
- Any secondary IgA nephropathy caused by Henoch-Schönlein purpura, ankylosing spondylitis, systemic lupus erythematosus, sjogren syndrome, viral hepatitis, liver cirrhosis, rheumatoid arthritis, mixed connective tissue disease, polyarteritis nodosa, erythema nodosum, psoriasis, ulcerative colitis, crohn's disease, tumor, AIDS ,etc.;
- Any nephropathy with special pathologic or clinical types, such as nephrotic syndrome, crescentic glomerulonephritis(with >50% of biopsied glomeruli), IgA nephropathy with minimal change disease (MCD-IgAN); and IgA nephropathy requiring corticosteroids treatment.
- Suffering from cardiovascular and cerebrovascular events (myocardial infarction, unstable angina, ventricular arrhythmia, New York heart association grade III-IV heart failure, stroke, etc.) within the last 12 weeks;
- Treating with systemic corticosteroids drug(excluding topical or nasal steroids) within 6 months prior to randomizing;
- Treating with systemic immunosuppressor within 6 months prior to randomizing: cyclophosphamide, azathioprine, mycophenolate mofetil, leflunomide, tacrolimus, cyclosporine, rituximab, tripterygium wilfordii, etc.;
- Requiring hospitalization or intravenous antibiotics treatment due to active infection within 6 months prior to randomizing;
- Active tuberculosis or latent carrier;
- Positive in herpes zoster, HIV antibody or HCV antibody;
- Active hepatitis or severe liver disease, and HBV infection (According to the HBV screening test, ①excluded the HBsAg-positive; ②HBsAg-negative and HBcAb-positive, the HBV-DNA should be tested to determine the situation: the HBV-DNA positive subjects should be excluded, while the HBV-DNA negative subjects can participated in.)
- With malignant tumors;
- Pregnancy or lactation, or patients with family planning during the experiment;
- Inevitably administrate nephrotoxic drugs during the study period;
- Allergy to human biological products;
- Receiving any other experimental drug 4 weeks or 5 times half-life of the experimental drug (up to the longer time) prior to randomizing;
- Not suitable for the study judged by investigator.
Sites / Locations
- Peking University people's hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
RC18 160mg
RC18 240mg
Placebo
Arm Description
RC18 160mg SC once weekly ,and total of 24 doses
RC18 240mg SC once weekly ,and total of 24 doses
Placebo SC once weekly ,and total of 24 doses
Outcomes
Primary Outcome Measures
Change from baseline in 24-hour urine protein excretion level at Week 24;
24-hour urine protein measures the amount of protein released in urine over a 24-hour period.
Secondary Outcome Measures
Change from baseline in eGFR
eGFR=Estimated Glomerular Filtration Rate
Change from baseline in urine protein/creatine ratio(UPCR) and/or urine albumin/ creatine ratio(UACR)
Each center tested for UPCR and / or UACR needs to be as consistent as possible.
Change from baseline in the count of urine red blood cells
The method of measuring the urine red blood cells in each center needs to be as consistent as possible.
Change from baseline in the values of Immunoglobulin G(IgG);
The content of IgG was detected by immunological index.
Change from baseline in the values of Immunoglobulin M(IgM);
The content of IgM was detected by immunological index.
Change from baseline in the values of Immunoglobulin A(IgA);
The content of IgG was detected by immunological index.
1. Change from baseline in the values of B-lymphocyte (CD19+)
The content of B-lymphocyte was detected by immunological index.
1. Change from baseline in the values of complement 3(C3)
The content of complement 3 was detected by immunological index.
1. Change from baseline in the values of complement 4 (C4)
The content of complement 4 was detected by immunological index.
The incidence rate and severity of adverse events.
To evaluate the safety of multiple intravitreal injection of each group.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04291781
Brief Title
A Study of RC18 Administered Subcutaneously to Subjects With IgA(Immunoglobulin A) Nephropathy
Official Title
Phase II Clinical Trial of RC18(Recombinant Human B Lymphocyte Stimulator Receptor - Antibody Fusion Protein for Injection) in the Treatment of IgA Nephropathy
Study Type
Interventional
2. Study Status
Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
April 13, 2020 (Actual)
Primary Completion Date
May 20, 2021 (Actual)
Study Completion Date
May 20, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
RemeGen Co., Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To evaluate the safety and efficacy of Tai Ai (Recombinant Human B Lymphocyte Stimulator Receptor-Antibody Fusion Protein for Injection) in the treatment of IgA nephropathy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
IgA Nephropathy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
44 (Actual)
8. Arms, Groups, and Interventions
Arm Title
RC18 160mg
Arm Type
Experimental
Arm Description
RC18 160mg SC once weekly ,and total of 24 doses
Arm Title
RC18 240mg
Arm Type
Experimental
Arm Description
RC18 240mg SC once weekly ,and total of 24 doses
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo SC once weekly ,and total of 24 doses
Intervention Type
Biological
Intervention Name(s)
RC18 160mg
Intervention Description
subcutaneous injection RC18 160mg on the upper arm, abdomen, or upper thigh outside;
Intervention Type
Biological
Intervention Name(s)
RC18 240mg
Intervention Description
subcutaneous injection RC18 240mg on the upper arm, abdomen, or upper thigh outside;
Intervention Type
Biological
Intervention Name(s)
placebo
Intervention Description
subcutaneous injection placebo on the upper arm, abdomen, or upper thigh outside;
Primary Outcome Measure Information:
Title
Change from baseline in 24-hour urine protein excretion level at Week 24;
Description
24-hour urine protein measures the amount of protein released in urine over a 24-hour period.
Time Frame
week 24
Secondary Outcome Measure Information:
Title
Change from baseline in eGFR
Description
eGFR=Estimated Glomerular Filtration Rate
Time Frame
week 0、4、8、12、16、20、24
Title
Change from baseline in urine protein/creatine ratio(UPCR) and/or urine albumin/ creatine ratio(UACR)
Description
Each center tested for UPCR and / or UACR needs to be as consistent as possible.
Time Frame
week 0、4、8、12、16、20、24
Title
Change from baseline in the count of urine red blood cells
Description
The method of measuring the urine red blood cells in each center needs to be as consistent as possible.
Time Frame
week 0、4、8、12、16、20、24
Title
Change from baseline in the values of Immunoglobulin G(IgG);
Description
The content of IgG was detected by immunological index.
Time Frame
week 0、4、8、12、16、20、24
Title
Change from baseline in the values of Immunoglobulin M(IgM);
Description
The content of IgM was detected by immunological index.
Time Frame
week 0、4、8、12、16、20、24
Title
Change from baseline in the values of Immunoglobulin A(IgA);
Description
The content of IgG was detected by immunological index.
Time Frame
week 0、4、8、12、16、20、24
Title
1. Change from baseline in the values of B-lymphocyte (CD19+)
Description
The content of B-lymphocyte was detected by immunological index.
Time Frame
week 0、4、8、12、16、20、24
Title
1. Change from baseline in the values of complement 3(C3)
Description
The content of complement 3 was detected by immunological index.
Time Frame
week 0、4、8、12、16、20、24
Title
1. Change from baseline in the values of complement 4 (C4)
Description
The content of complement 4 was detected by immunological index.
Time Frame
week 0、4、8、12、16、20、24
Title
The incidence rate and severity of adverse events.
Description
To evaluate the safety of multiple intravitreal injection of each group.
Time Frame
week 0、4、8、12、16、20、24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signing the informed consent;
Biopsy confirmed diagnosis of IgA nephropathy;
Male or female, between 18 and 70 years age;
Before randomization, 24-hour urine protein excretion of ≥1g/24h in every screening visit;
Estimated glomerular filtration rate (eGFR) (CKD-EPI formula) of >45 ml/min per 1.73m2;
Have received the ACEI(Angiotension converting enzyme inhibitors)/ARB(Angiotensin receptor blocker) standard treatment for 24 weeks prior to randomization, and have stabled the dosage (within the maximum tolerated dosage) for 4 weeks prior to randomization.
Exclusion Criteria:
Significant abnormalities in clinical laboratory values (including, but not limited to, the following indicators):
Items Abnormal value WBC(white blood cell count) <3*10^9/L PMN(Neutrophil count) <1.5*10^9/L HGB(hemoglobin) <85g/L PLT(blood platelet count) <80*10^9/L TBil(total bilirubin) >1.5*ULN ALT(Alanine aminotransferase) >3*ULN AST( Aspartate transaminase) >3*ULN ALP(alkaline phosphatase) >2*ULN CK(creatine kinase) >5*ULN
Any secondary IgA nephropathy caused by Henoch-Schönlein purpura, ankylosing spondylitis, systemic lupus erythematosus, sjogren syndrome, viral hepatitis, liver cirrhosis, rheumatoid arthritis, mixed connective tissue disease, polyarteritis nodosa, erythema nodosum, psoriasis, ulcerative colitis, crohn's disease, tumor, AIDS ,etc.;
Any nephropathy with special pathologic or clinical types, such as nephrotic syndrome, crescentic glomerulonephritis(with >50% of biopsied glomeruli), IgA nephropathy with minimal change disease (MCD-IgAN); and IgA nephropathy requiring corticosteroids treatment.
Suffering from cardiovascular and cerebrovascular events (myocardial infarction, unstable angina, ventricular arrhythmia, New York heart association grade III-IV heart failure, stroke, etc.) within the last 12 weeks;
Treating with systemic corticosteroids drug(excluding topical or nasal steroids) within 6 months prior to randomizing;
Treating with systemic immunosuppressor within 6 months prior to randomizing: cyclophosphamide, azathioprine, mycophenolate mofetil, leflunomide, tacrolimus, cyclosporine, rituximab, tripterygium wilfordii, etc.;
Requiring hospitalization or intravenous antibiotics treatment due to active infection within 6 months prior to randomizing;
Active tuberculosis or latent carrier;
Positive in herpes zoster, HIV antibody or HCV antibody;
Active hepatitis or severe liver disease, and HBV infection (According to the HBV screening test, ①excluded the HBsAg-positive; ②HBsAg-negative and HBcAb-positive, the HBV-DNA should be tested to determine the situation: the HBV-DNA positive subjects should be excluded, while the HBV-DNA negative subjects can participated in.)
With malignant tumors;
Pregnancy or lactation, or patients with family planning during the experiment;
Inevitably administrate nephrotoxic drugs during the study period;
Allergy to human biological products;
Receiving any other experimental drug 4 weeks or 5 times half-life of the experimental drug (up to the longer time) prior to randomizing;
Not suitable for the study judged by investigator.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hong Zhang, M.D.
Organizational Affiliation
Peking University First Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Peking University people's hospital
City
Beijing
State/Province
Beijing
Country
China
12. IPD Sharing Statement
Learn more about this trial
A Study of RC18 Administered Subcutaneously to Subjects With IgA(Immunoglobulin A) Nephropathy
We'll reach out to this number within 24 hrs